FCM
SER icon

Fourpath Capital Management’s Serina Therapeutics SER Stock Holding History

Fourpath Capital Management’s Portfolio SER Stock Details SER Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-2
Closed -$13 – 771
2024
Q3 		$13 Buy
+2
New +$16 ﹤0.01% 775

Other funds holding SER

BC
Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return
WA
Waverly Advisors Birmingham, Alabama $13.4B AUM 18.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return
KP
Keel Point Huntsville, Alabama $1.51B AUM 20.06% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fourpath Capital Management's SER Position: Q4 2024 in Review

Fourpath Capital Management sold out of Serina Therapeutics (SER) in Q4 2024, closing a stake of 2 shares — an estimated $13 sold.

Fourpath Capital Management first reported a position in SER in Q3 2024 and held it in 1 quarter. The position peaked at $13 in Q3 2024. 25 funds tracked by Wall St. Rank hold SER as of Q4 2024.

  • Fourpath Capital Management reported no remaining Serina Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Fourpath Capital Management sold 2 Serina Therapeutics shares in Q4 2024, an estimated $13.
  • Fourpath Capital Management first reported a position in Serina Therapeutics in Q3 2024 and held it in 1 quarter.
  • Fourpath Capital Management's Serina Therapeutics position peaked at $13 in Q3 2024.
  • 25 funds tracked by Wall St. Rank held Serina Therapeutics as of Q4 2024.

Based on Fourpath Capital Management's 13F filing for Q4 2024, filed 24 Jan 2025.